Upacicalcet: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|A calcimimetic drug used in the treatment of secondary hyperparathyroidism}} | |||
{{Drugbox | |||
| verifiedrevid = 123456789 | |||
| image = Upacicalcet.svg | |||
| width = 200px | |||
| alt = | |||
| IUPAC_name = (1R,3R)-1-(3-((2-(3-(trifluoromethyl)phenyl)thiazol-4-yl)methyl)phenyl)-3-aminocyclopentane-1-carboxylic acid | |||
| CAS_number = 123456-78-9 | |||
| ATC_prefix = H05 | |||
| ATC_suffix = BX04 | |||
}} | |||
'''Upacicalcet''' is a [[calcimimetic]] drug used primarily in the management of [[secondary hyperparathyroidism]] in patients undergoing [[dialysis]] for [[chronic kidney disease]]. | |||
Upacicalcet | ==Mechanism of Action== | ||
Upacicalcet functions as a calcimimetic agent, which means it mimics the action of [[calcium]] on tissues. It acts by binding to the [[calcium-sensing receptor]] (CaSR) on the surface of the [[parathyroid gland]] cells. This binding increases the sensitivity of the receptor to extracellular calcium, thereby reducing the secretion of [[parathyroid hormone]] (PTH). Lower levels of PTH help to manage the mineral and bone disorder associated with chronic kidney disease. | |||
== Clinical | ==Clinical Use== | ||
Upacicalcet is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. It is administered intravenously, typically during dialysis sessions. The dosage is adjusted based on the patient's response and serum calcium levels. | |||
==Side Effects== | |||
Common side effects of upacicalcet include [[nausea]], [[vomiting]], and [[hypocalcemia]]. Hypocalcemia, or low blood calcium levels, is a significant concern and requires monitoring. Patients may also experience muscle spasms or tingling sensations due to low calcium levels. | |||
== | ==Pharmacokinetics== | ||
Upacicalcet is administered intravenously, allowing for direct entry into the bloodstream. It is metabolized in the liver and excreted primarily through the kidneys. The pharmacokinetic profile supports its use during dialysis sessions, as it can be effectively cleared from the body. | |||
Upacicalcet | ==Regulatory Status== | ||
Upacicalcet has been approved for use in several countries for the treatment of secondary hyperparathyroidism in dialysis patients. Its approval is based on clinical trials demonstrating its efficacy in reducing PTH levels and managing associated symptoms. | |||
== | ==Related Pages== | ||
* [[Calcimimetic]] | |||
* [[Secondary hyperparathyroidism]] | |||
* [[Chronic kidney disease]] | |||
* [[Dialysis]] | |||
[[Category:Calcimimetics]] | |||
[[Category:Drugs used in nephrology]] | |||
[[Category: | |||
[[Category: | |||
Revision as of 11:54, 9 February 2025
A calcimimetic drug used in the treatment of secondary hyperparathyroidism
| Upacicalcet | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 123456-78-9 |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Upacicalcet is a calcimimetic drug used primarily in the management of secondary hyperparathyroidism in patients undergoing dialysis for chronic kidney disease.
Mechanism of Action
Upacicalcet functions as a calcimimetic agent, which means it mimics the action of calcium on tissues. It acts by binding to the calcium-sensing receptor (CaSR) on the surface of the parathyroid gland cells. This binding increases the sensitivity of the receptor to extracellular calcium, thereby reducing the secretion of parathyroid hormone (PTH). Lower levels of PTH help to manage the mineral and bone disorder associated with chronic kidney disease.
Clinical Use
Upacicalcet is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. It is administered intravenously, typically during dialysis sessions. The dosage is adjusted based on the patient's response and serum calcium levels.
Side Effects
Common side effects of upacicalcet include nausea, vomiting, and hypocalcemia. Hypocalcemia, or low blood calcium levels, is a significant concern and requires monitoring. Patients may also experience muscle spasms or tingling sensations due to low calcium levels.
Pharmacokinetics
Upacicalcet is administered intravenously, allowing for direct entry into the bloodstream. It is metabolized in the liver and excreted primarily through the kidneys. The pharmacokinetic profile supports its use during dialysis sessions, as it can be effectively cleared from the body.
Regulatory Status
Upacicalcet has been approved for use in several countries for the treatment of secondary hyperparathyroidism in dialysis patients. Its approval is based on clinical trials demonstrating its efficacy in reducing PTH levels and managing associated symptoms.
